Seaport Therapeutics, Inc. Common Stock Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Seaport Therapeutics, Inc. Common Stock (SPTX) holds an ST Score of 73.5 out of 100 (B+), with its strongest factor being Financial Strength (A) and its weakest Growth (B). Analysts rate SPTX Buy across 1 ratings with a $37.33 average price target (+0.7% vs the current $21.39).
- Strongest
- Financial StrengthA
- Weakest
- GrowthB
All factor grades
- Financial StrengthA
- ValuationA-
- ForecastB+
- ProfitabilityB
- MomentumB
- GrowthB
Contact
SPTX stock: frequently asked questions
What is SPTX's ST Score?
Seaport Therapeutics, Inc. Common Stock (SPTX) has an ST Score of 73.5 out of 100, an overall grade of B+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SPTX a buy, sell, or hold?
Wall Street's consensus rating on SPTX is Buy based on 1 analyst ratings. Our own ST Score grades it B+ (73.5/100). This is data, not investment advice — always do your own research.
What is SPTX's valuation grade?
Seaport Therapeutics, Inc. Common Stock (SPTX) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SPTX's growth grade?
Seaport Therapeutics, Inc. Common Stock (SPTX) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SPTX's profitability grade?
Seaport Therapeutics, Inc. Common Stock (SPTX) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SPTX's financial strength grade?
Seaport Therapeutics, Inc. Common Stock (SPTX) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SPTX?
The average analyst price target for Seaport Therapeutics, Inc. Common Stock (SPTX) is $37.33 from 1 analysts, which is +0.7% versus the recent price of $21.39.